ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
11 announcements with these filters
Aurobindo Pharma received USFDA final approval for its first MDI product, Beclomethasone Dipropionate HFA Inhalation Aerosol. The US market for this segment is estimated at US$301 million.
Aurobindo Pharma's subsidiary acquired A1 Biochem USA Inc for ₹9.47 Crore. This 100% acquisition expands its contract research and development services capabilities in the USA.
Aurobindo Pharma's subsidiary, A1 Biochem Labs (India), invested USD 1,000,000 (approx. ₹9.5 Crore) to incorporate and capitalize a new US subsidiary, A1 Biochem USA Inc.
Aurobindo Pharma announced that the US FDA inspection of its subsidiary Apitoria Pharma's Unit-IV concluded with zero observations. This signals continued regulatory compliance for the facility.
Aurobindo Pharma's subsidiary, Apitoria Pharma, incorporated a new wholly owned subsidiary named Avogent Lifesciences. The initial capital subscription for this pharmaceutical entity is Rs. 5 Crore.
Aurobindo Pharma's subsidiary, Lannett Company LLC, launched the generic version of Advair Diskus® in the US. This marks the company's first commercialized product from its inhalation pipeline.
Aurobindo Pharma held its 39th Annual General Meeting on August 27, 2026, to discuss financial statements, dividend, and director reappointments as per the AGM agenda.
Aurobindo Pharma reported the completion of a US FDA inspection at its subsidiary, Lannett Company LLC, which resulted in four procedural observations.
Aurobindo Pharma's subsidiary, Eugia Pharma Specialities Ltd., received a US FDA Warning Letter for its Unit I manufacturing facility. The unit contributes approximately 2% to group revenue.
Q1FY27 revenue grew 16% YoY to ₹9,150 Cr. EBITDA margin stood at 21% with PAT of ₹1,032 Cr. Focus remains on complex generics, Lannett integration, and biosimilar monetization.
Aurobindo Pharma incorporated a new wholly owned subsidiary, 'Auropharm Overseas Limited'. The company subscribed to the subsidiary's share capital of Rs. 0.1 Crore.